Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-44396
Titel: Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model
VerfasserIn: Holländer, Sebastian
von Heesen, Maximilian
Gäbelein, Gereon
Mercier, Julie
Laschke, Matthias W.
Menger, Michael D.
Glanemann, Matthias
Spiliotis, Antonios E.
Sprache: Englisch
Titel: Scientific Reports
Bandnummer: 15
Heft: 1
Verlag/Plattform: Springer Nature
Erscheinungsjahr: 2025
Freie Schlagwörter: Obesity
Non-alcoholic fatty liver disease
Hepatectomy
Cilostazol
Liver regeneration
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Cilostazol has previously been shown to reduce liver steatosis and enhance hepatic perfusion. We investigated the effects of cilostazol after major hepatectomy in a steatotic rat model. Six weeks prior to surgery, Sprague–Dawley rats were fed with a high-fructose diet. The treatment group received daily 5 mg/kg cilostazol. Seven days following the cilostazol treatment, all animals underwent 70% liver resection (PHX). Analysis of hepatic blood flow and microcirculation and immunohistochemical examinations were conducted 30 min after PHX (postoperative day [POD] 0) as well as on POD 1, POD 3 and POD 7. The weight of cilostazol-treated animals was significantly reduced compared to untreated controls after completion of the 6-week high-FRC diet. Furthermore, 41% macrovesicular steatosis was found in the control group compared to 8% in the cilostazol group. Hepatic arterial and portal venous perfusion were increased in the cilostazol group on POD 7. Lower liver enzyme release was found postoperatively in cilostazol-treated animals. Moreover, apoptosis and neutrophil infiltration were reduced after cilostazol treatment. Proliferation of hepatocytes and liver regeneration after PHX were significantly increased in the cilostazol group. Consequently, cilostazol should be evaluated as a novel strategy to reduce the rate of liver failure after PHX in steatotic liver.
DOI der Erstveröffentlichung: 10.1038/s41598-025-87135-z
URL der Erstveröffentlichung: https://www.nature.com/articles/s41598-025-87135-z
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-443964
hdl:20.500.11880/39659
http://dx.doi.org/10.22028/D291-44396
ISSN: 2045-2322
Datum des Eintrags: 14-Feb-2025
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Chirurgie
Professur: M - Prof. Dr. Matthias Glanemann
M - Prof. Dr. Michael D. Menger
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
s41598-025-87135-z.pdf2,22 MBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons